The impact of glucagon and exenatide on oxidative stress levels and antioxidative enzyme expression in in vitro induced steatosis in HepG2 cell culture
Abstract
Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a healthcare issue of growing concern. Its development is multifactorial, and it is more commonly seen in obese patients. In those circumstances, intracellular lipid overload ensues, resulting in oxidative stress that might be responsible for progression toward steatohepatitis. Novel therapeutic approaches that are effective in weight management are expected to improve the course of MASLD. One of the potential mechanisms involved in such protective properties may relate to the reduction in oxidative stress.
Material and methods: The induction of steatosis and the assessment of oxidative stress level and expression of antioxidant enzymes (superoxide dismutase — SOD, glutathione peroxidase — GPx and catalase — Cat) in HepG2 hepatoma cell line subjected to glucagon and exenatide treatment.
Results: Exenatide monotherapy successfully reduced lipid accumulation by 25%. Significant reductions in markers of oxidative stress (reactive oxygen species and malondialdehyde) were obtained in cells subjected to combined treatment with glucagon and exenatide (by 24 and 21%, respectively). Reduced burden of oxidative stress was associated with elevated expression of SOD and GPx but not Cat.
Conclusions: Combined activation of glucagon-like peptide-1 (GLP-1) and glucagon receptors reduces oxidative stress in HepG2 steatotic cell cultures. This observation may stem from increased antioxidative potential.
Keywords: exenatideglucagonGLP-1MASLDliver steatosisoxidative stressantioxidantHepG2
References
- Bołdys A, Bułdak Ł, Maligłówka M, et al. Potential Therapeutic Strategies in the Treatment of Metabolic-Associated Fatty Liver Disease. Medicina (Kaunas). 2023; 59(10).
- Avcı E, Kucukoduk A. Choroidal vascular changes in non-alcoholic fatty liver disease. Endokrynol Pol. 2023; 74(4): 430–436.
- Belli LS, Perricone G, Adam R, et al. all the contributing centers (www.eltr.org) and the European Liver and Intestine Transplant Association (ELITA). Impact of DAAs on liver transplantation: Major effects on the evolution of indications and results. An ELITA study based on the ELTR registry. J Hepatol. 2018; 69(4): 810–817.
- Wong RJ, Aguilar M, Cheung R, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015; 148(3): 547–555.
- van Herpen NA, Schrauwen-Hinderling VB. Lipid accumulation in non-adipose tissue and lipotoxicity. Physiol Behav. 2008; 94(2): 231–241.
- Mello T, Zanieri F, Ceni E, et al. Oxidative Stress in the Healthy and Wounded Hepatocyte: A Cellular Organelles Perspective. Oxid Med Cell Longev. 2016; 2016: 8327410.
- Delli Bovi AP, Marciano F, Mandato C, et al. Oxidative Stress in Non-alcoholic Fatty Liver Disease. An Updated Mini Review. Front Med (Lausanne). 2021; 8: 595371.
- Pandey KB, Rizvi SI. Markers of oxidative stress in erythrocytes and plasma during aging in humans. Oxid Med Cell Longev. 2010; 3(1): 2–12.
- Bułdak Ł, Łabuzek K, Bułdak RJ, et al. Exenatide (a GLP-1 agonist) improves the antioxidative potential of in vitro cultured human monocytes/macrophages. Naunyn Schmiedebergs Arch Pharmacol. 2015; 388(9): 905–919.
- Bułdak Ł, Machnik G, Skudrzyk E, et al. The impact of exenatide (a GLP-1 agonist) on markers of inflammation and oxidative stress in normal human astrocytes subjected to various glycemic conditions. Exp Ther Med. 2019; 17(4): 2861–2869.
- Bułdak Ł, Skudrzyk E, Machnik G, et al. Exenatide improves antioxidant capacity and reduces the expression of LDL receptors and PCSK9 in human insulin secreting 1.1E7 cell line subjected to hyperglycemia and oxidative stress. Postepy Hig Med Dosw . 2022; 76(1): 16–23.
- Khalifa O, H Mroue K, Mall R, et al. Investigation of the Effect of Exendin-4 on Oleic Acid-Induced Steatosis in HepG2 Cells Using Fourier Transform Infrared Spectroscopy. Biomedicines. 2022; 10(10).
- Nahra R, Wang T, Gadde KM, et al. Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study. Diabetes Care. 2021; 44(6): 1433–1442.
- Parker VER, Robertson D, Erazo-Tapia E, et al. Cotadutide promotes glycogenolysis in people with overweight or obesity diagnosed with type 2 diabetes. Nat Metab. 2023; 5(12): 2086–2093.
- Spandidos A, Wang X, Wang H, et al. PrimerBank: a resource of human and mouse PCR primer pairs for gene expression detection and quantification. Nucleic Acids Res. 2010; 38(Database issue): D792–D799.
- Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001; 25(4): 402–408.
- Schindelin J, Arganda-Carreras I, Frise E, et al. Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012; 9(7): 676–682.
- Maseko TE, Elkalaf M, Peterová E, et al. Comparison of HepaRG and HepG2 cell lines to model mitochondrial respiratory adaptations in non‑alcoholic fatty liver disease. Int J Mol Med. 2024; 53(2).
- Chen X, Li L, Liu X, et al. Oleic acid protects saturated fatty acid mediated lipotoxicity in hepatocytes and rat of non-alcoholic steatohepatitis. Life Sci. 2018; 203: 291–304.
- Li T, Gong H, Zhan B, et al. Chitosan oligosaccharide attenuates hepatic steatosis in HepG2 cells via the activation of AMP-activated protein kinase. J Food Biochem. 2022; 46(5): e14045.
- Myint M, Oppedisano F, De Giorgi V, et al. Inflammatory signaling in NASH driven by hepatocyte mitochondrial dysfunctions. J Transl Med. 2023; 21(1): 757.
- Tsikas D. Assessment of lipid peroxidation by measuring malondialdehyde (MDA) and relatives in biological samples: Analytical and biological challenges. Anal Biochem. 2017; 524: 13–30.
- Zelber-Sagi S, Ivancovsky-Wajcman D, Fliss-Isakov N, et al. Serum Malondialdehyde is Associated with Non-Alcoholic Fatty Liver and Related Liver Damage Differentially in Men and Women. Antioxidants (Basel). 2020; 9(7).
- Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023; 77(5): 1797–1835.
- Sun T, Zhang B, Ru QJ, et al. Tocopheryl quinone improves non-alcoholic steatohepatitis (NASH) associated dysmetabolism of glucose and lipids by upregulating the expression of glucagon-like peptide 1 (GLP-1) restoring the balance of intestinal flora in rats. Pharm Biol. 2021; 59(1): 723–731.
- Zhao Z, Zhao F, Zhang Y, et al. Risk factors of dapagliflozin-associated diabetic ketosis/ketoacidosis in patients with type 2 diabetes mellitus: A matched case-control study. Diabetes Res Clin Pract. 2023; 196: 110236.
- Gu Y, Sun L, He Y, et al. Comparative efficacy of glucagon-like peptide 1 (GLP-1) receptor agonists, pioglitazone and vitamin E for liver histology among patients with nonalcoholic fatty liver disease: systematic review and pilot network meta-analysis of randomized controlled trials. Expert Rev Gastroenterol Hepatol. 2023; 17(3): 273–282.
- Gao H, Zeng Z, Zhang H, et al. The Glucagon-Like Peptide-1 Analogue Liraglutide Inhibits Oxidative Stress and Inflammatory Response in the Liver of Rats with Diet-Induced Non-alcoholic Fatty Liver Disease. Biol Pharm Bull. 2015; 38(5): 694–702.
- Buldak L, Machnik G, Skudrzyk E, et al. Exenatide prevents statin-related LDL receptor increase and improves insulin secretion in pancreatic beta cells (1.1E7) in a protein kinase A-dependent manner. J Appl Biomed. 2022; 20(4): 130–140.
- Zhu CG, Luo Y, Wang H, et al. Liraglutide Ameliorates Lipotoxicity-Induced Oxidative Stress by Activating the NRF2 Pathway in HepG2 Cells. Horm Metab Res. 2020; 52(7): 532–539.
- Yu X, Hao M, Liu Yu, et al. Liraglutide ameliorates non-alcoholic steatohepatitis by inhibiting NLRP3 inflammasome and pyroptosis activation via mitophagy. Eur J Pharmacol. 2019; 864: 172715.
- Engström A, Wintzell V, Melbye M, et al. Association of glucagon-like peptide-1 receptor agonists with serious liver events among patients with type 2 diabetes: A Scandinavian cohort study. Hepatology. 2024; 79(6): 1401–1411.
- Patel V, Joharapurkar A, Kshirsagar S, et al. Coagonist of GLP-1 and glucagon decreases liver inflammation and atherosclerosis in dyslipidemic condition. Chem Biol Interact. 2018; 282: 13–21.
- Nahra R, Wang T, Gadde KM, et al. Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study. Diabetes Care. 2021; 44(6): 1433–1442.
- Xue Y, Wei Y, Cao L, et al. Protective effects of scutellaria-coptis herb couple against non-alcoholic steatohepatitis via activating NRF2 and FXR pathways in vivo and in vitro. J Ethnopharmacol. 2024; 318(Pt A): 116933.
- Kiani B, Yarahmadi S, Nabi-Afjadi M, et al. Comprehensive Review on the Metabolic Cooperation Role of Nuclear Factor E2-Related Factor 2 and Fibroblast Growth Factor 21 against Homeostasis Changes in Diabetes. Clin Diabetol. 2022; 11(6): 409–419.
- Müller F, Sturla S. Human in vitro models of nonalcoholic fatty liver disease. Curr Opin Toxicol. 2019; 16: 9–16.
- Gerets HHJ, Tilmant K, Gerin B, et al. Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins. Cell Biol Toxicol. 2012; 28(2): 69–87.
- Huggett ZJ, Smith A, De Vivo N, et al. A Comparison of Primary Human Hepatocytes and Hepatoma Cell Lines to Model the Effects of Fatty Acids, Fructose and Glucose on Liver Cell Lipid Accumulation. Nutrients. 2022; 15(1).
![](https://journals.viamedica.pl/plugins/generic/popups/images/icons/close.png)